Relocation of the
European Medicines Agency


Where the world comes to work



Dublin’s established life sciences community makes it a natural fit for the European Medicines Agency

Following Brexit, the European Medicines Agency (EMA) will need regulatory expertise and support, and a community of life sciences experts, to support its swift and seamless relocation. Ireland has a strong medical heritage as a global centre for pharmaceutical manufacturing and innovation that gave the world the portable defibrillator, the modern stethoscope and the hypodermic syringe.

The Dublin-based Health Products Regulatory Authority (HPRA) has an international reputation of regulatory excellence and a firmly established working relationship with the EMA and international counterparts. The HPRA has a demonstrated ability to evolve and adapt, and the agency’s already significant support of the EMA can be rapidly scaled up in the event of relocation.

Ireland is home to 75 international pharmaceutical companies, including nine of the top ten global pharmaceutical manufacturers and 13 of the world’s top 15 medical device companies. It is no surprise, then, that Ireland is the world’s seventh largest exporter of medical and pharmaceutical products.

Ireland has a long tradition of pharmaceutical operations excellence, attracting major foreign investment in life sciences for over 50 years. Following a wave of investment in biologics manufacturing, Ireland is now home to over 20 individual biotech facilities, and has secured more than €10 billion of new investments in biotech manufacturing facilities in the last decade alone.

Over 29,000 people are directly employed by medical device companies in Ireland - the highest number of personnel per capita employed in medtech in Europe. Innovation for future healthcare will increasingly centre on the convergence between medical devices, pharmaceuticals and communication technologies, and all three drivers come together in Dublin.

Relocating to Dublin will ensure business continuity at all levels of EMA operations with the support of a highly regarded medicines regulator, an established life sciences community, and a large pool of highly qualified life sciences professionals.

*Original Article -

Back to news